Vincent B R, Buttin G
Somatic Cell Genet. 1979 Jan;5(1):67-82. doi: 10.1007/BF01538787.
Variants isolated from mutagenized Chinese hamster fibroblasts by a single cycle of exposure to ara-C distributed into two classes: (1) deoxycytidine (dC) kinase deficient clones with a high level of resistance, this phenotype was recessive in hybrids; and (2) clones exhibiting joint resistance to thymidine (dT) and to "low" ara-C concentration, this phenotype was accounted for by an increased dCTP pool. The incorporation of exogenous dC into macromolecules was markedly altered in these variants. In hybrids, the phenotype of joint resistance to dT and ara-C was semidominant. Through a second selection step, variants cumulating recessive high resistance to ara-C and semidominant dT resistance were recovered. The identification of these two classes of ara-C-resistant variants suggests an interpretation of the known phenotypes of ara-C resistance as manifestations of chromosomal gene mutations. Dominant resistance mutations might contribute to the survival of cancer cells during prolonged ara-C chemotherapy.
通过单次暴露于阿糖胞苷(ara-C)从诱变的中国仓鼠成纤维细胞中分离出的变体分为两类:(1)具有高抗性水平的脱氧胞苷(dC)激酶缺陷型克隆,该表型在杂种中是隐性的;(2)对胸苷(dT)和“低”阿糖胞苷浓度表现出联合抗性的克隆,该表型是由于dCTP池增加所致。在这些变体中,外源性dC掺入大分子的情况发生了显著改变。在杂种中,对dT和阿糖胞苷的联合抗性表型是半显性的。通过第二个选择步骤,回收了对阿糖胞苷累积隐性高抗性和对dT半显性抗性的变体。这两类阿糖胞苷抗性变体的鉴定表明,将已知的阿糖胞苷抗性表型解释为染色体基因突变的表现。显性抗性突变可能有助于癌细胞在长期阿糖胞苷化疗期间存活。